Patents by Inventor Bassil I. Dahiyat

Bassil I. Dahiyat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunoglobulin insertions, deletions and substitutions
    Patent number: 8101720
    Abstract: An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more Fc?Rs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide.
    Type: Grant
    Filed: January 25, 2008
    Date of Patent: January 24, 2012
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Bassil I. Dahiyat, Wei Dang, Sher Bahadur Karki, Omid Vafa
  • Fc variants with altered binding to FcRn
    Patent number: 8088376
    Abstract: The present application relates to a variant Fc region comprising the double mutation 428L/434S that increases serum half-life and the numbering is according to the EU index.
    Type: Grant
    Filed: January 18, 2011
    Date of Patent: January 3, 2012
    Assignee: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Optimized anti-CD20 monoclonal antibodies having Fc variants
    Patent number: 8084582
    Abstract: The present invention relates to optimized CD20 antibodies having Fc variants, methods for their generation, and method for their application, such as methods of enhancing macrophage activation, particularly for therapeutic purposes.
    Type: Grant
    Filed: June 30, 2005
    Date of Patent: December 27, 2011
    Assignee: Xencor, Inc.
    Inventors: Bassil I. Dahiyat, Gregory Alan Lazar, Omid Vafa
  • FC VARIANTS WITH ALTERED BINDING TO FCRN
    Publication number: 20110110928
    Abstract: The present application relates to a variant Fc region comprising the double mutation 428L/434S that increases serum half-life and the numbering is according to the EU index.
    Type: Application
    Filed: January 18, 2011
    Publication date: May 12, 2011
    Applicant: Xencor, Inc.
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • IgG Immunoglobulin Variants with Optimized Effector Function
    Publication number: 20100317834
    Abstract: The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
    Type: Application
    Filed: August 24, 2010
    Publication date: December 16, 2010
    Applicant: Xencor, Inc.
    Inventors: Gregory Alan Lazar, Bassil I. Dahiyat, Wei Dang, Sher Bahadur Karki, Omid Vafa
  • Fc Variants with altered binding to FcRn
    Publication number: 20100234573
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Application
    Filed: February 1, 2010
    Publication date: September 16, 2010
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Fc Variants with altered binding to FcRn
    Publication number: 20100234574
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Application
    Filed: February 1, 2010
    Publication date: September 16, 2010
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • FC VARIANTS WITH ALTERED BINDING TO FCRN
    Publication number: 20100234575
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Application
    Filed: February 1, 2010
    Publication date: September 16, 2010
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • FC VARIANTS WITH ALTERED BINDING TO FCRN
    Publication number: 20100234571
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Application
    Filed: February 1, 2010
    Publication date: September 16, 2010
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Fc Variants with altered binding to FcRn
    Publication number: 20100234572
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Application
    Filed: February 1, 2010
    Publication date: September 16, 2010
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Fc Variants with altered binding to FcRn
    Publication number: 20100204454
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Application
    Filed: February 1, 2010
    Publication date: August 12, 2010
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Fc VARIANTS WITH ALTERED BINDING TO FcRn
    Publication number: 20090163699
    Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
    Type: Application
    Filed: December 22, 2008
    Publication date: June 25, 2009
    Inventors: Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
  • Fc VARIANTS WITH ALTERED BINDING TO FcRn
    Publication number: 20090041770
    Abstract: The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
    Type: Application
    Filed: October 31, 2007
    Publication date: February 12, 2009
    Inventors: Aaron Keith CHAMBERLAIN, Bassil I. Dahiyat, John Rudolph Desjarlais, Sher Bahadur Karki
  • Anti-Glypican-3 Antibody
    Publication number: 20080267979
    Abstract: An anti-glypican-3 antibody comprising one or more amino acid substitutions introduced in the Fc region is disclosed. Preferably, in the anti-glypican-3 antibody, one or more of the amino acid residues at the positions 239, 298, 326, 330 and 332 in the Fc region are substituted with other amino acid residues. Since the Fc-modified anti-glypican-3 antibody of the invention exhibit enhanced ADCC activity, it is useful in treating cancers, such as hepatic cancer. Also disclosed are an anticancer agent comprising the anti-glypican-3 antibody of the invention and a pharmaceutically acceptable carrier, as well as a method of treating a patient with cancer comprising administering to the patient the anticancer agent of the invention.
    Type: Application
    Filed: October 11, 2006
    Publication date: October 30, 2008
    Inventors: Gregory Alan Lazar, Bassil I. Dahiyat, Hisafumi Okabe, Masamichi Sugimoto, Shigeyuki Iijima, Izumi Sugo
  • Protein Design Automation for Protein Libraries
    Publication number: 20080167194
    Abstract: The invention relates to the use of protein design automation (PDA) to generate computationally prescreened secondary libraries of proteins, and to methods and compositions utilizing the libraries.
    Type: Application
    Filed: October 30, 2007
    Publication date: July 10, 2008
    Applicant: Xencor, Inc.
    Inventors: Bassil I. Dahiyat, Robert J. Hayes, Jorg Bentzien, Klaus M. Fiebig
  • Protein design automation for protein libraries
    Patent number: 7379822
    Abstract: The invention relates to the use of protein design automation (PDA) to generate computationally prescreened secondary libraries of proteins, and to methods and compositions utilizing the libraries.
    Type: Grant
    Filed: September 18, 2003
    Date of Patent: May 27, 2008
    Assignee: Xencor
    Inventors: Bassil I. Dahiyat, Robert J. Hayes, Jöerg Bentzien, Klaus M. Fiebig
  • Protein design automation for protein libraries
    Patent number: 7315786
    Abstract: The invention relates to the use of protein design automation (P DA) to generate computationally prescreened secondary libraries of proteins, and to methods and compositions utilizing the libraries.
    Type: Grant
    Filed: August 10, 2001
    Date of Patent: January 1, 2008
    Assignee: Xencor
    Inventors: Bassil I. Dahiyat, Jörg Bentzien, Klaus M. Fiebig, Robert J. Hayes
  • TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
    Patent number: 7244823
    Abstract: The invention relates to novel proteins with TNF-alpha antagonist activity and nucleic acids encoding these proteins. The invention further relates to the use of the novel proteins in the treatment of TNF-alpha related disorders.
    Type: Grant
    Filed: September 30, 2002
    Date of Patent: July 17, 2007
    Assignee: Xencor
    Inventors: Bassil I. Dahiyat, John R. Desjarlais, Anton Filikov, Umesh Muchhal, Malu Lourdes G. Tansey, Jonathan Zalevsky
  • Nucleic acids and protein variants of hG-CSF with granulopoietic activity
    Patent number: 7208473
    Abstract: The invention relates to novel granulopoietic activity (GPA) proteins and nucleic acids. The invention further relates to the use of the GPA proteins in the treatment of G-CSF related disorders.
    Type: Grant
    Filed: August 1, 2003
    Date of Patent: April 24, 2007
    Assignee: Xencor, Inc.
    Inventors: Bassil I. Dahiyat, Peizhi Luo
  • TNF-?variants
    Patent number: 7101974
    Abstract: The invention relates to novel proteins with TNF-? antagonist activity and nucleic acids encoding these proteins. The invention further relates to the use of the novel proteins in the treatment of TNF-? related disorders, such as rheumatoid arthritis.
    Type: Grant
    Filed: October 15, 2001
    Date of Patent: September 5, 2006
    Assignee: Xencor
    Inventors: Bassil I. Dahiyat, Anton Filikov